David A Loeffler
Overview
Explore the profile of David A Loeffler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
541
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loeffler D
J Alzheimers Dis
. 2024 Jun;
100(2):379-411.
PMID: 38875041
Amyloid protein-β (Aβ) concentrations are increased in the brain in both early onset and late onset Alzheimer's disease (AD). In early onset AD, cerebral Aβ production is increased and its...
2.
Loeffler D
Front Aging Neurosci
. 2024 Jun;
16:1368200.
PMID: 38872626
Clearance of amyloid-beta (Aβ) from the brain is impaired in both early-onset and late-onset Alzheimer's disease (AD). Mechanisms for clearing cerebral Aβ include proteolytic degradation, antibody-mediated clearance, blood brain barrier...
3.
Loeffler D
J Alzheimers Dis Rep
. 2023 Sep;
7(1):873-899.
PMID: 37662616
Immunotherapeutic efforts to slow the clinical progression of Alzheimer's disease (AD) by lowering brain amyloid-β (Aβ) have included Aβ vaccination, intravenous immunoglobulin (IVIG) products, and anti-Aβ monoclonal antibodies. Neither Aβ...
4.
Loeffler D
J Neurochem
. 2023 Jan;
164(6):725-763.
PMID: 36633092
Cerebral clearance of amyloid β-protein (Aβ) is decreased in early-onset and late-onset Alzheimer's disease (AD). Aβ is cleared from the brain by enzymatic degradation and by transport out of the...
5.
Loeffler D
J Alzheimers Dis
. 2021 Jan;
80(1):1-27.
PMID: 33459643
There is an extensive literature relating to factors associated with the development of Alzheimer's disease (AD), but less is known about factors which may contribute to its progression. This review...
6.
Loeffler D
Front Neurol
. 2020 Jun;
11:459.
PMID: 32547478
Grifols' recent Alzheimer Management by Albumin Replacement ("AMBAR") study investigated the effects of plasmapheresis with albumin replacement, plus intravenous immunoglobulin (IVIG) in some subjects, in patients with mild-to-moderate Alzheimer's disease...
7.
Loeffler D, Aasly J, LeWitt P, Coffey M
J Parkinsons Dis
. 2019 Jul;
9(3):467-488.
PMID: 31322581
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common known cause of autosomal dominant Parkinson's disease (PD) and sporadic PD (sPD). The clinical presentation of LRRK2...
8.
Loeffler D
Front Aging Neurosci
. 2019 Mar;
11:49.
PMID: 30914945
Misfolded proteins are pathological findings in some chronic neurodegenerative disorders including Alzheimer's, Parkinson's, and Huntington's diseases. Aging is a major risk factor for these disorders, suggesting that the mechanisms responsible...
9.
Loeffler D, Klaver A, Coffey M, Aasly J
Front Aging Neurosci
. 2018 Jun;
10:130.
PMID: 29867441
Autophagy removes both functional and damaged intracellular macromolecules from cells via lysosomal degradation. Three autophagic mechanisms, namely macroautophagy, chaperone-mediated autophagy (CMA), and microautophagy, have been described in mammals. Studies in...
10.
Klaver A, Coffey M, Aasly J, Loeffler D
Brain Res
. 2018 Feb;
1683:12-16.
PMID: 29456132
Lysosome-associated membrane glycoprotein 2 (lamp2) plays critical roles in chaperone-mediated autophagy (CMA) and macroautophagy. Its isoform lamp2a is decreased in Parkinson's disease (PD) substantia nigra. Mutations in the leucine-rich repeat...